|
|
|
|
|
|
|
|
 |
|
|
|
Management James R. McNab, Jr., Chairman and CEO Mr. McNab serves as Chairman and CEO of eNOS Pharmaceuticals. He has started several successful companies including Parker Medical, manufacturer and worldwide supplier of orthopedic and sports-related products. Reprogenesis, Inc., a regenerative therapy company that merged into Curis, Inc. (NASDAQ: CRIS), and Sontra Medical, Inc., a privately held ultrasound-based diagnostics and transdermal delivery company. His expertise consists of management and development of intellectual property assets, development of corporate strategies, managing growth, and utilizing capital markets. Mr. McNab serves on the Board of Directors at Curis, Inc. and at Sontra Medical. Mr. McNab received a B.A. in Economics from Davidson College and a M.B.A. from the University of North Carolina at Chapel Hill. Timothy A. Jamieson, M.D., Ph.D., Chief Medical Officer Dr. Jamieson serves on the board of eNOS Pharmaceuticals and is the chief medical officer. He received his B.S. in Chemical Engineering from Penn State and M.D. and Ph.D. in Molecular Biology from the University of Virginia. Dr. Jamieson did his Radiation Oncology residency at Duke University where he won the American Radium Society’s Young Oncologist Award for his research in tumor suppressor genes in head and neck cancer. He is currently a partner in the Florida & Georgia Radiation Oncology Group, Chairman of the non profit CMAP which provides healthcare for the uninsured working poor in southeast Georgia, and a partner in K2 Urbancorp, a real estate development company in Tallahassee, Florida. Eyal S. Ron, Ph.D., Chief Scientific Officer Dr. Eyal S. Ron serves as Chief Scientific Officer. He directs the critical activities (pre-clinical, clinical and regulatory) required to move product candidates forward in the development process. Dr. Ron has over 20 years of experience in the development of drugs, biomaterials and drug delivery systems. He was an integral member of the team which founded Alkermes (EnzyTech), Combinent BioMedical Systems, Cerebrotech, Focal, GelMed/Gel Sciences and InfiMed. In these companies, Dr. Ron initiated development programs resulting in products that are currently on the market or in late-stage clinical trials. He is the author of over 100 papers, book chapters, and abstracts. He has been granted inventor status on more than 30 patents, principally in the areas of drug formulations and delivery, tissue engineering, and biomaterials. Dr. Ron received a B.Sc. in Chemistry from Tel Aviv University and a Ph.D. in Chemistry from Brandeis University. He was a Post Doctoral Fellow with Professor Robert Langer at MIT and is currently on the Adjunct Faculty at the Harvard-MIT Division of Health and Sciences and Technology. |
|
|
|
|
|